Egle Therapeutics vs Tridek-One
Egle Therapeutics
Modulating T-regulatory cells to balance immunity
45 employees · est. 2020 · Paris, France
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
12 employees · est. 2018 · Paris, France
Tridek-One is the older company (2020 vs 2018).
Side-by-Side Comparison
| Metric | Egle Therapeutics | Tridek-One |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2018 older |
| Headquarters | ||
| Headquarters | Paris, France | Paris, France |
| Employees | ||
| Employees | 45 | 12 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care, Life Sciences |
| Funding Stage | ||
| Funding Stage | Grant | Venture round |
| Total Funding | ||
| Total Funding | $49.30M | $19.00M |
| Funding Rounds | ||
| Funding Rounds | 2 | 2 |
| Services | ||
| Services | developing breakthrough therapies designed to modulate regulatory T cells for the treatment of cancer and autoimmune diseases | Development of first-in-class CD31 checkpoint agonists for the treatment of autoimmune and inflammatory diseases. |
| Target Customers | ||
| Target Customers | patients with cancer and autoimmune diseases | Patients with autoimmune and inflammatory diseases, healthcare providers, pharmaceutical companies, and biotech research institutions. |
| Taxonomy | ||
| Taxonomy | ImmunomodulationT-regulatory CellsImmunotherapyOncologyAutoimmune DiseasesImmune Suppressor +6 | ImmunomodulationTherapeutic AntibodiesAutoimmune DiseasesInflammatory DisordersBiopharmaceuticalsImmunotherapy +8 |
| Website | ||
| Website | egle-tx.com | tridekone.com |
About Egle Therapeutics
Egle Therapeutics is a biotechnology startup based in France, founded in 2020. The company focuses on modulating T-regulatory cells (Tregs) to balance immunity, employing a unique concept that involves starving Tregs while specifically targeting the most immunosuppressive ones. Egle Therapeutics rec...
About Tridek-One
Tridek-One is a French biotechnology startup founded in 2018, specializing in the development of first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company's focus on anti-CD31 ago...
Also comparing in this category
Comparing more than these two?
Get Egle Therapeutics, Tridek-One and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does Egle Therapeutics compare?
A PDF of Egle Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Rival Readout
Comparing competitors? We do this properly.
10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.
Frequently Asked Questions
Compare Egle Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Egle Therapeutics on 11 Jun 2025, and Tridek-One on 7 Jun 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
